Form 4: Repligen COO James Bylund Granted Equity Awards

Repligen Corporation's Chief Operating Officer, James Bylund, was granted 7,751 restricted stock units and 8,315 stock options.

Summary

• James Bylund, Chief Operating Officer of Repligen Corporation (RGEN), received equity awards on March 5, 2026.
• The awards consist of 7,751 restricted stock units (RSUs) and 8,315 stock options.
• Each RSU represents a contingent right to receive one share of Repligen Corporation's Common Stock.
• The RSUs will vest in equal annual installments over a three-year period, commencing on March 5, 2027.
• The stock options have an exercise price of $141.91 and are set to expire on March 5, 2036.
• One-third of the stock options will vest and become exercisable annually on March 5, 2027, March 5, 2028, and March 5, 2029.
• Following these transactions, Mr. Bylund beneficially owns 25,423 shares of Common Stock directly and 8,315 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a routine and positive development for corporate governance, as it aligns executive incentives with long-term shareholder value, without indicating any immediate operational or financial changes.

Positives

• The grant of restricted stock units and stock options aligns the Chief Operating Officer's interests with long-term shareholder value.
• The three-year vesting schedule encourages retention and sustained performance from a key executive.

Future Outlook

This filing does not contain forward-looking statements or guidance beyond the specified vesting and expiration dates of the granted equity awards.

Industry Context

StockSavvy.ai notes that equity grants to key executives like the Chief Operating Officer are a standard practice in the biotechnology and life sciences tools industry, aiming to incentivize long-term performance and align executive interests with shareholder returns. This type of compensation is common for retaining talent in competitive sectors.

Comparison to Industry Standards

• The grant of RSUs and stock options with a multi-year vesting schedule is a common compensation structure for C-suite executives in the biotech and life sciences sector, comparable to practices at companies like Danaher Corporation or Sartorius AG, which also utilize performance-based equity to retain and motivate leadership.
• The specific number of units and options granted would typically be benchmarked against peer companies of similar market capitalization and revenue within the industry, considering the executive's role and performance. Without specific peer compensation data, a direct quantitative comparison is not possible from this filing alone.

Related Party Transactions

• The equity grant to James Bylund, the Chief Operating Officer, constitutes a related party transaction as part of his executive compensation.

Stakeholder Impact

• Shareholders: The equity grant aligns the COO's interests with long-term shareholder value, potentially leading to better executive performance and stock appreciation.
• Employees: May signal stability in executive leadership and a commitment to performance-based compensation within the company.

Next Steps

• The restricted stock units will begin vesting on March 5, 2027, and continue annually for three years.
• The stock options will begin vesting on March 5, 2027, and continue annually for three years.

Key Dates

Recommendation

This Form 4 filing reports a routine executive compensation grant and does not provide new information that would fundamentally alter the investment thesis for Repligen Corporation. It reinforces the standard practice of aligning executive incentives with long-term company performance, which is generally a neutral to slightly positive factor. Investors should continue to hold based on broader company fundamentals and market conditions, as this specific filing does not warrant a change in recommendation.

Keywords

Repligen, RGEN, Form 4, Insider Transaction, Stock Grant, Restricted Stock Units, Stock Options, Executive Compensation, James Bylund, Chief Operating Officer